Perioperative Management of Anticoagulation in Gynecologic Patients
12/1/2015 - Christopher M. Zahn, MD
Editor: Eduardo Lara-Torre, MD
For patients using chronic antithrombotic therapy undergoing gynecologic surgery, interruption of therapy to reduce bleeding risk must be balanced against risk of thromboembolism. Patients may benefit from “bridging” therapy, in which a short-acting anticoagulant (low-molecular weight heparin [LMWH] or unfractionated heparin) is used in the perioperative period. The decision to use bridging therapy depends on individualized risk assessment, including patient preferences and the potential use of multidisciplinary input.
Risk assessment may include use of an instrument such as the CHADS2 (Congestive Heart Failure-Hypertension-Age-Diabetes-Stroke) score to predict risk of stroke. Risk of bleeding and of thromboembolism may also be predicted; Tables 2-4 in ACOG Committee Opinion # 610 define risk and the associated recommended management protocols for perioperative anticoagulation. Other considerations include the type of thromboembolism (arterial or venous) and individual patient characteristics (such as age, BMI, mobility), which may upgrade or downgrade recommendations. Patients with a personal history of thromboembolism more than 12 months before their planned surgery may avoid anticoagulation unless the patient has an active malignancy. Patients with a mechanical heart valve may be at high risk; consultation with a cardiologist to define risk and management is generally advised.
Bridging protocols may incorporate LMWH or unfractionated heparin, and are generally divided into low- and high-dose regimens. Low-dose is considered “prophylactic”, involving once- (e.g. 40 mg enoxaparin) or twice-daily (e.g. 30 mg enoxaparin) LMWH or subcutaneous heparin (5,000 – 7,500 IU twice daily). High dose (“therapeutic”) regimens include LMWH (1 mg/kg twice daily or 1.5 mg/kg once daily) or intravenous unfractionated heparin to achieve an APTT 1.5 – 2 times control. Therapeutic dosing regimens have been the most widely studied for bridging therapy.
Vitamin K antagonist (warfarin) therapy is typically stopped 5 days before surgery, and bridging therapy (if used) is started. Patients with higher INR on vitamin K antagonist therapy may need to stop earlier. INR should be checked the day before surgery; if not normalized, oral Vitamin K (1 -2 mg) is recommended. When using bridging therapy, therapeutic dosing is stopped 24 hours before surgery when using LMWH, and 6 hours for intravenous unfractionated heparin. Subcutaneous unfractionated heparin should be stopped the night before the procedure. Thromboprophylaxis should be administered with pneumatic compression devises and possibly prophylactic heparin dosing depending on the risks of thromboembolism and bleeding.
If adequate hemostasis is present, vitamin K antagonist therapy may begin 12 – 24 hours postoperatively. Patients receiving bridge therapy with therapeutic dosing, and who have undergone surgery with a high risk of bleeding, may re-start therapy 48 – 72 hours postoperatively. Bridging therapy is continued until the INR reaches a therapeutic range.
Antiplatelet Therapy (aspirin, clopidogrel)
Bridging therapy is typically not recommended for patients on antiplatelet agents. For patients using aspirin at high risk of a cardiovascular event, aspirin should be continued because the benefit outweighs the risk of bleeding. Patients at low risk should stop aspirin 7 – 10 days before surgery and re-start it with a similar schedule to the vitamin K antagonist recommendations. Clopidogrel should be stopped 5 – 7 days before surgery, and therapeutic dose re-started 12 – 24 hours postoperatively.
Less is known about perioperative management for patents using target-specific anticoagulants such as rivaroxaban, apixaban, and dabigatran. Possible schemes include stopping therapy 5 days before surgery with bridging therapy, or stopping 1 – 5 days before without bridging therapy. Consultation with a hematologist, cardiologist, or primary care provider may be beneficial for managing these patients.
Women receiving vitamin K antagonists may require vitamin K (1 – 2 mg) to reverse the anticoagulation effects and decrease the delay for surgery. IV heparin may be used as bridging therapy if the nature and urgency of the procedure allow.
Chronic antithrombotic therapy and gynecologic surgery. Committee Opinion No. 610. American College of Obstetricians and Gynecologists. Obstet Gynecol 2014;124:856–62.
Douketis JD, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. American College of Chest Physicians. Chest 2012; 141:e326S-350S
Initial Approval: December 2015. Reaffirmed May 2017.Back to Search Results